Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||no benefit||Cetuximab + Cisplatin + Vinorelbine||Phase III||Actionable||In a Phase III clinical trial, the addition of Erbitux (cetuximab) to Platinol (cisplatin) and Navelbine (vinorelbine) chemotherapy resulted in improved median overall survival of 11.3 months, compared to 10.1 months with chemotherapy alone, and an overall response rate of 36% (203/557) vs. 29% (166/568) with chemotherapy alone in patients with non-small cell lung cancer (PMID: 19410716).||19410716|